Relmada Therapeutics
RLMD
110 hedge funds and large institutions have $66.6M invested in Relmada Therapeutics in 2022 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 29 increasing their positions, 34 reducing their positions, and 57 closing their positions.
342% more call options, than puts
Call options by funds: $7.39M | Put options by funds: $1.67M
15% less repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 34
18% less funds holding
Funds holding: 134 → 110 (-24)
22.17% less ownership
Funds ownership: 85.77% → 63.6% (-22%)
39% less first-time investments, than exits
New positions opened: 35 | Existing positions closed: 57
93% less capital invested
Capital invested by funds: $954M → $66.6M (-$887M)
100% less funds holding in top 10
Funds holding in top 10: 7 → 0 (-7)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$20.9M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$9.66M |
| 3 |
Millennium Management
New York
|
+$9.15M |
| 4 |
Two Sigma Investments
New York
|
+$4.17M |
| 5 |
Walleye Capital
New York
|
+$4.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$88.2M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$76.9M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$74M |
| 4 |
VA
VR Adviser
New York
|
-$56.2M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$31M |
RLMD Hedge Fund Activity: Q4 2022 in Review
110 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Relmada Therapeutics (RLMD) for Q4 2022, worth a combined $66.6M — down 93% from $954M a quarter earlier.
Sellers outnumbered buyers: 57 funds closed out of RLMD and 35 opened new positions — a net loss of 22 holders — while 34 trimmed existing stakes and 29 added.
The largest buyer was Deep Track Capital, adding an estimated $20.9M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $88.2M sold.
- 110 institutional investors held Relmada Therapeutics (RLMD) as of Q4 2022, down from 134 in Q3 2022.
- Funds reported $66.6M of Relmada Therapeutics stock for Q4 2022, down 93% quarter-over-quarter.
- 35 funds opened new Relmada Therapeutics positions in Q4 2022 and 57 closed out, a net change of -22 holders.
- The largest Relmada Therapeutics buyer in Q4 2022 was Deep Track Capital, an estimated $20.9M added.
- The largest Relmada Therapeutics seller in Q4 2022 was Perceptive Advisors, an estimated $88.2M sold.
Based on aggregated 13F filings for Q4 2022.